AstraZeneca (LSE:AZN) (NYSE:AZN) (STO:AZN) has been awarded Breakthrough Therapy Designation (BTD) in the United States for Tagrisso (osimertinib), the biopharmaceutical company announced on Thursday.
This designation relates to the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumour resection with curative intent.
It comes after the Phase III ADAURA trial, in which Tagrisso reduced the risk of disease recurrence or death by around 80%.
BTD is granted by the US Food and Drug Administration to accelerate the development and regulatory review of potential new medicines that are intended to treat a serious condition and address a significant unmet medical need. Eligible medicines are expected to show encouraging early clinical results that demonstrate substantial improvement on a clinically significant endpoint over available medicines.
Tagrisso is already approved for the first-line treatment of patients with metastatic EGFRm NSCLC and for the treatment of metastatic EGFR T790M mutation-positive NSCLC in the US, Japan, China, the EU and other countries around the world.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial